Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction

被引:813
作者
Ridker, PM
Rifai, N
Pfeffer, M
Sacks, F
Lepage, S
Braunwald, E
机构
[1] Brigham & Womens Hosp, Leducq Ctr Mol & Genet Epidemiol Cardiovasc Disor, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Ctr Cardiovasc Prevent, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Div Cardiovasc Dis, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Childrens Hosp, Med Ctr,Dept Pathol, Boston, MA USA
[6] Ctr Univ Sante Estrie, Sherbrooke, PQ, Canada
关键词
inflammation; myocardial infarction; tumor necrosis factor; atherosclerosis;
D O I
10.1161/01.CIR.101.18.2149
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Levels of tumor necrosis factor-alpha (TNF-alpha) increase with acute ischemia. However, whether elevations of TNF-alpha in the stable phase after myocardial ischemia (MI) are associated with increased risk of recurrent coronary events is unknown. Methods and Results-A nested case-control design was used to compare TNF-alpha levels obtained an average of 8.9 months after initial MI among 272 participants in the Cholesterol And Recurrent Events (CARE) trial who subsequently developed recurrent nonfatal MI or a fatal cardiovascular event (cases) and from an equal number of age- and sex-matched participants who remained free of these events during follow-up (controls). Overall, TNF-alpha levels were significantly higher among cases than controls (2.84 versus 2.57 pg/mL, P=0.02). The excess risk of recurrent coronary events after MT was predominantly seen among those with the highest levels of TNF-alpha, such that those with levels in excess of 4.17 pg/mL (the 95th percentile of the control distribution) had an approximate to 3-fold increase in risk (RR=2.7, 95% CI 1.4 to 5.2, P=0.004). Risk estimates were independent of other risk factors and were similar in subgroup analyses limited to cardiovascular death (RR=2.1) or to recurrent nonfatal MI (RR=3.2), Conclusions-Plasma concentrations of TNF-alpha are persistently elevated among post-MI patients at increased risk for recurrent coronary events. These data support the hypothesis that a persistent inflammatory instability is present among stable patients at increased vascular risk. Novel therapies designed to attenuate inflammation may thus represent a new direction in the treatment of MI.
引用
收藏
页码:2149 / 2153
页数:5
相关论文
共 31 条
[1]   DETECTION AND LOCALIZATION OF TUMOR NECROSIS FACTOR IN HUMAN ATHEROMA [J].
BARATH, P ;
FISHBEIN, MC ;
CAO, J ;
BERENSON, J ;
HELFANT, RH ;
FORRESTER, JS .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (05) :297-302
[2]   SERUM TUMOR-NECROSIS-FACTOR LEVELS IN ACUTE MYOCARDIAL-INFARCTION AND UNSTABLE ANGINA-PECTORIS [J].
BASARAN, Y ;
BASARAN, MM ;
BABACAN, KF ;
ENER, B ;
OKAY, T ;
GOK, H ;
OZDEMIR, M .
ANGIOLOGY, 1993, 44 (04) :332-337
[3]   Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability [J].
Biasucci, LM ;
Liuzzo, G ;
Grillo, RL ;
Caligiuri, G ;
Rebuzzi, AG ;
Buffon, A ;
Summaria, F ;
Ginnetti, F ;
Fadda, G ;
Maseri, A .
CIRCULATION, 1999, 99 (07) :855-860
[4]   Elevated levels of interleukin-6 in unstable angina [J].
Biasucci, LM ;
Vitelli, A ;
Liuzzo, G ;
Altamura, S ;
Caligiuri, G ;
Monaco, C ;
Rebuzzi, AG ;
Ciliberto, G ;
Maseri, A .
CIRCULATION, 1996, 94 (05) :874-877
[5]   Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events [J].
Biasucci, LM ;
Liuzzo, G ;
Fantuzzi, G ;
Caligiuri, G ;
Rebuzzi, AG ;
Ginnetti, F ;
Dinarello, CA ;
Maseri, A .
CIRCULATION, 1999, 99 (16) :2079-2084
[6]   Induction of nuclear factor kappa B and activation protein 1 in postischemic myocardium [J].
Chandrasekar, B ;
Freeman, GL .
FEBS LETTERS, 1997, 401 (01) :30-34
[7]   Mechanisms of disease: Acute-phase proteins and other systemic responses to inflammation [J].
Gabay, C ;
Kushner, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (06) :448-454
[8]  
Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5
[9]  
HEGEWISCH S, 1990, LANCET, V336, P294
[10]  
HERSKOWITZ A, 1995, AM J PATHOL, V146, P419